BNT162b2 mRNA COVID-19 vaccine shows excellent efficacy in patients with IBD

Key clinical point: Preliminary real-world data show excellent efficacy of BNT162b2 mRNA COVID-19 vaccine with very low absolute breakthrough infection rate in fully vaccinated patients with inflammatory bowel disease (IBD), which was comparable to that of the reference population.

Major finding: The rate of breakthrough infection more than 7 and 14 days after the second dose in patients with IBD vs matched reference cohort was 0.19% vs 0.15% and 0.14% vs 0.10%, respectively. The relative risk for breakthrough infection among patients with IBD vs matched cohort more than 7 and 14 days after the second dose was 1.21 (95% confidence interval [CI], 0.74-1.97) and 1.26 (95% CI, 0.71-2.23), respectively.

Study details: Findings are from a retrospective cohort study of 12,231 BNT162b2 mRNA COVID-19 vaccines with IBD-aged 16 years and older from the Maccabi Healthcare Services IBD registry and 36,254 vaccinated matched reference patients.

Disclosures: The study received no external funding. The authors declared no conflicts of interest.

Source: Ben-Tov A et al. Gastroenterology. 2021 Jul 2. doi: 10.1053/j.gastro.2021.06.076.

Key clinical point: Preliminary real-world data show excellent efficacy of BNT162b2 mRNA COVID-19 vaccine with very low absolute breakthrough infection rate in fully vaccinated patients with inflammatory bowel disease (IBD), which was comparable to that of the reference population.

Major finding: The rate of breakthrough infection more than 7 and 14 days after the second dose in patients with IBD vs matched reference cohort was 0.19% vs 0.15% and 0.14% vs 0.10%, respectively. The relative risk for breakthrough infection among patients with IBD vs matched cohort more than 7 and 14 days after the second dose was 1.21 (95% confidence interval [CI], 0.74-1.97) and 1.26 (95% CI, 0.71-2.23), respectively.

Study details: Findings are from a retrospective cohort study of 12,231 BNT162b2 mRNA COVID-19 vaccines with IBD-aged 16 years and older from the Maccabi Healthcare Services IBD registry and 36,254 vaccinated matched reference patients.

Disclosures: The study received no external funding. The authors declared no conflicts of interest.

Source: Ben-Tov A et al. Gastroenterology. 2021 Jul 2. doi: 10.1053/j.gastro.2021.06.076.

Key clinical point: Preliminary real-world data show excellent efficacy of BNT162b2 mRNA COVID-19 vaccine with very low absolute breakthrough infection rate in fully vaccinated patients with inflammatory bowel disease (IBD), which was comparable to that of the reference population.

Major finding: The rate of breakthrough infection more than 7 and 14 days after the second dose in patients with IBD vs matched reference cohort was 0.19% vs 0.15% and 0.14% vs 0.10%, respectively. The relative risk for breakthrough infection among patients with IBD vs matched cohort more than 7 and 14 days after the second dose was 1.21 (95% confidence interval [CI], 0.74-1.97) and 1.26 (95% CI, 0.71-2.23), respectively.

Study details: Findings are from a retrospective cohort study of 12,231 BNT162b2 mRNA COVID-19 vaccines with IBD-aged 16 years and older from the Maccabi Healthcare Services IBD registry and 36,254 vaccinated matched reference patients.

Disclosures: The study received no external funding. The authors declared no conflicts of interest.

Source: Ben-Tov A et al. Gastroenterology. 2021 Jul 2. doi: 10.1053/j.gastro.2021.06.076.